Please assess the completion status of the following clinical trial:

Trial Title: Liraglutide in the Treatment of Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with type 1 diabetes mellitus: Fasting c-peptide \< 0.1nmol/l on insulin therapy for more than 12 months with or without history of diabetic ketoacidosis.~2. Using a continuous glucose monitoring device (CGM) and regularly measuring their blood sugars four times daily~3. HbA1c of less than 8.5%.~4. Well versed with carbohydrate counting~5. Age 18-75 years~Exclusion Criteria:~1. Type 1 diabetes for less than 12 months;~2. Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks;~3. Hepatic disease (transaminase \> 3 times normal) or cirrhosis;~4. Renal impairment (serum creatinine \> 1.5);~5. HIV or Hepatitis C positive status;~6. Participation in any other concurrent clinical trial;~7. Any other life-threatening, non-cardiac disease;~8. Use of an investigational agent or therapeutic regimen within 30 days of study.~9. history of pancreatitis~10. pregnancy~11. inability to give informed consent~12. history of gastroparesis~13. history of medullary thyroid carcinoma or MEN 2 syndrome.~14. Family history of MEN 2, Family history of medullary thyroid cancer, or familial medullary thyroid cancer~15. Women of childbearing potential who are not using adequate contraception 16) Women who are pregnant

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Daily Injection
- Liraglutide 1.8mg (Type: ACTIVE_COMPARATOR): Daily Injection
- Liraglutide 1.2mg (Type: ACTIVE_COMPARATOR): Daily injections
- Liraglutide 0.6 mg (Type: ACTIVE_COMPARATOR): Daily injection

Based on this trial design, predict the completion outcome and termination type (if applicable).